Oct 30, 2025 04:01PM
Sep 11, 2025 06:48AM
Sep 10, 2025 10:30AM
Sep 10, 2025 10:11AM
Sep 10, 2025 09:58AM
Sep 10, 2025 07:01AM
Sep 10, 2025 07:01AM Travere Therapeutics Provides Update on FDA Advisory Committee Meeting for FILSPARI® (sparsentan) in FSGS
Aug 7, 2025 10:06AM
Aug 6, 2025 04:01PM
Jul 6, 2025 10:00AM
Jul 1, 2025 10:00AM
Jun 28, 2025 10:00AM
Jun 23, 2025 11:55AM
Jun 18, 2025 12:13PM INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc.  - TVTX
Jun 15, 2025 10:00AM
Jun 10, 2025 09:00AM
Jun 6, 2025 11:44AM
Jun 2, 2025 01:30PM
May 28, 2025 09:00AM
May 22, 2025 09:00AM
May 22, 2025 09:00AM INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc.  - TVTX
May 16, 2025 09:24AM
May 16, 2025 04:20AM
May 15, 2025 04:22PM
May 15, 2025 04:05PM
Nov 7, 2024 07:00AM
Aug 6, 2024 04:01PM
Nov 8, 2023 04:01PM Ligand Reports Third Quarter 2023 Financial Results
Aug 4, 2022 07:00AM
Aug 4, 2022 07:00AM
Aug 3, 2022 04:05PM
Aug 3, 2022 04:05PM
Aug 3, 2022 04:05PM
May 16, 2022 07:05AM
May 16, 2022 07:00AM Travere Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Sparsentan for the Treatment of IgA Nephropathy
May 16, 2022 07:00AM
Feb 28, 2022 06:14AM

15,649 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All